Randomized pilot study of lacosamide versus phenytoin in acute exacerbations of trigeminal neuralgia
This randomized pilot study in Mexico City found that while both intravenous lacosamide and phenytoin demonstrated high short-term efficacy for acute trigeminal neuralgia exacerbations, lacosamide was associated with significantly fewer adverse events, supporting the need for a larger confirmatory trial.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body's nerves are like a massive, high-speed internet network, constantly sending messages about touch, temperature, and pain from your face to your brain. Usually, this network runs smoothly. But sometimes, a specific cable—the trigeminal nerve, which handles sensation for your face—gets crossed wires. When this happens, it doesn't just send a "ouch" signal; it sends a screaming, electric-shock alarm that feels like a lightning bolt striking your cheek. This condition is called trigeminal neuralgia, and it's one of the most painful things a human can experience.
When the pain gets too wild for normal pills to handle, doctors have to switch to "emergency mode," using strong medicines injected directly into the vein to calm the nerves down fast. For a long time, the go-to "fire extinguisher" for these electrical storms has been a drug called phenytoin. It works well, but it's a bit like a sledgehammer: it stops the pain, but it often knocks the patient out with dizziness, makes them feel woozy, or even causes their heart to skip a beat. Scientists have been wondering if there's a newer, more precise tool—a "laser scalpel" instead of a sledgehammer—that could stop the pain just as fast but without the messy side effects. That's the big question this study set out to answer.
The Race to Calm the Storm
In this study, researchers in Mexico City decided to put two different "fire extinguishers" head-to-head in a race to see which one could stop the pain of a trigeminal neuralgia attack faster and safer. They gathered 57 adults who were in the middle of a severe pain crisis and couldn't be helped by their usual pills. They split these brave volunteers into two teams: one team got the old-school sledgehammer (phenytoin), and the other got the newer, sleeker tool (lacosamide).
The goal was simple: could the new drug stop the pain just as well as the old one, but without making the patient feel like they were on a rollercoaster?
The Results: A Tie on Pain, A Win on Safety
When the researchers checked the results two hours after the medicine was injected, the answer regarding pain relief was a statistical tie. Both drugs were incredibly effective.
- The Phenytoin Team: 27 out of 30 patients (90.0%) saw their pain drop by at least half.
- The Lacosamide Team: 25 out of 27 patients (92.6%) saw their pain drop by at least half.
In fact, both groups were so successful that the difference between them was so tiny it could easily be chalked up to chance. The study suggests that if you are in a pain crisis, either drug will likely turn the volume down on the pain quickly.
However, the story changes completely when we look at how the patients felt while the drugs were working. This is where the new drug, lacosamide, really shined.
- Phenytoin: Almost everyone in this group (93.3%) had some kind of side effect. The most common complaints were feeling lightheaded, pain at the injection site, and extreme sleepiness. One patient even developed a serious balance issue called cerebellar syndrome.
- Lacosamide: Only about half of the patients (55.6%) had any side effects, and none of them were serious. The side effects that did happen were much milder, like a little nausea or a bit of sleepiness.
The math shows that patients taking lacosamide were significantly less likely to get hit with side effects compared to those taking phenytoin. It's like comparing a car that gets you to your destination in the same amount of time but with a much smoother ride and no nausea.
What This Means (And What It Doesn't)
The researchers are careful to say that while these results are exciting, this was a "pilot study," which is like a dress rehearsal before the big show. Because the group of people was relatively small, they can't say with 100% certainty that lacosamide is definitely better for everyone, but the evidence strongly suggests it is a safer option that works just as well.
The study didn't find any reason to stop using phenytoin, but it did find a very strong reason to try lacosamide first. It suggests that doctors might be able to stop the electrical storms in the face without the "collateral damage" of dizziness and heart issues that often come with the older drug.
The authors conclude that lacosamide looks like a promising new hero for this specific type of pain. They believe it's time for a bigger, more detailed study to confirm these findings, but for now, the data suggests we might finally have a way to stop the pain without making the patient feel terrible in the process.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.